Washington, DC 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 11, 2019


ContraVir Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)







(State or other jurisdiction




IRS Employer

of incorporation or organization)


File Number)


Identification No.)


399 Thornall Street, First Floor

Edison, NJ 08837

(Address of principal executive offices)


Registrant’s telephone number, including area code: (732) 902-4000



(Former name or former address, if changed since last report)


Securities registered pursuant to Section 12(b) of the Act:


Title of each class:


Trading Symbol(s)


Name of each exchange on which registered:

Common Stock




Nasdaq Capital Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x





Item 8.01                                           Other Events


On June 11, 2019, ContraVir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the peer-reviewed journal, PLOS ONE, has published the Company’s research article entitled “The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice.”  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.


Item 9.01                                           Financial Statements and Exhibits


(d) Exhibits




ContraVir Pharmaceuticals, Inc. Press Release dated June 11, 2019




Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 11, 2019











/s/ Robert Foster



Robert Foster



Chief Executive Officer



Exhibit 99.1


ContraVir Pharmaceuticals Announces Publication of CRV431 Data from

Experimental Model of Hepatitis B


EDISON, N.J., June 11, 2019 - ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that the peer-reviewed journal, PLOS ONE, has published ContraVir’s research article entitled “The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice.”


“The research article reports our discovery that CRV431 greatly reduces HBV DNA in the liver of transgenic mice in a dose-dependent manner,” said Dr. Robert Foster, Chief Executive Officer of ContraVir. “CRV431 interferes with the way that HBV hijacks our body’s molecules to amplify virus replication, which is distinct from traditional antiviral drugs such as tenofovir that bind only to HBV proteins. Additionally, CRV431 reduced serum levels of HBsAg, an important prognostic indicator, which is typically not decreased by nucleotide drugs. This study suggests that CRV431 and tenofovir can be used in combination to significantly decrease HBV DNA levels in the liver, and we are conducting further studies to elucidate CRV431’s mechanism of action.”


The article describes a study where Hepatitis B virus (“HBV”) transgenic mice were treated with CRV431, a cyclophilin inhibitor; and/or tenofovir exalidex (“TXL”), a nucleotide prodrug. Mice were treated daily for a period of 16 days receiving either 10 mg/kg of CRV431; 50 mg/kg of CRV431; 5 mg/kg of TXL; 10 mg/kg of TXL; a combination of 10 mg/kg of CRV431 and 5 mg/kg of TXL; or vehicle control. Key findings of the study include:


·                  CRV431 decreased liver HBV DNA levels dose-dependently, where the low (10 mg/kg/day) and high (50 mg/kg/day) doses of CRV431 reduced HBV DNA levels by 13% and 91%, respectively, compared to the vehicle group.


·                  TXL also decreased liver HBV DNA levels dose-dependently, where the low (5 mg/kg/day) and high (10 mg/kg/day) doses of TXL reduced HBV DNA levels by 55% and 97%, respectively, compared to the vehicle group.


·                  In mice that were co-dosed with the lowest tested doses of CRV431 (10 mg/kg/day) and TXL (5 mg/kg/day), liver HBV DNA decreased by 80% compared to the vehicle group.


The article may be accessed at: https://doi.org/10.1371/journal.pone.0217433


About ContraVir Pharmaceuticals


ContraVir is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an




important role in the overall treatment of liver disease - from triggering events through to end-stage disease. For more information, please visit www.contravir.com.


Forward Looking Statements


Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on ContraVir’s current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products.  There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir’s Form 10-K for the year ended December 31, 2018 and other periodic reports filed with the Securities and Exchange Commission.


For further information, please contact:


Stephen Kilmer

ContraVir Investor Relations

(646) 274-3580